Clusterin overexpression and relapse-free survival in breast cancer
- Authors
- Yom, C.K.[Yom, C.K.]; Woo, H.-Y.[Woo, H.-Y.]
- Issue Date
- 2009
- Keywords
- Breast; Carcinoma; Clusterin; Relapse-free survival
- Citation
- Anticancer Research, v.29, no.10, pp.3909 - 3912
- Indexed
- SCOPUS
- Journal Title
- Anticancer Research
- Volume
- 29
- Number
- 10
- Start Page
- 3909
- End Page
- 3912
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/79669
- ISSN
- 0250-7005
- Abstract
- Background: The prognostic significance of the antiapoptotic protein secretory clusterin overexpression in breast cancer is unclear. Patients and Methods: Secretory clusterin expression was explained in three hundred and fifty-two patients with breast cancer by immunohistochemistry. Clusterin overexpression was tested for correlation with overall survival (OS) and relapse-free survival (RFS). Results: The overall frequency of clusterin overexpression was 52% (178 out of 342) in breast cancer; 44% for in situ carcinomas and 53% for invasive cancer. Among fifty-six patients with tumor recurrence, clusterin overexpression was found in 74% (14 out of 19) in breast cancer <T2 stage and 51% (19 out of 37) in ≥T2 stage breast cancer. The Kaplan-Meier analysis revealed that clusterin overexpression was a prognostic factor for RFS in breast cancer <T2 stage (mean RFS, 79.8 vs. 73.5 months, p=0.044). Conclusion: Our results suggest that clusterin overexpression might be a predictive factor for recurrence in <T2 stage breast cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.